Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Melisi

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 27, 2005
Key cancer cell signal transduction pathways as therapeutic targetsRoberto Bianco, Davide Melisi, Fortunato Ciardiello, et al.
Current Pharmaceutical Design|October 25, 2014
Pancreatic cancer: systemic combination therapies for a heterogeneous diseaseDavide Melisi, Lorenzo Calvetti, Melissa Frizziero, et al.
Current Drug Metabolism|August 13, 2015
Current Strategies to Overcome Resistance to ALK-Inhibitor AgentsFrancesca Simionato, Melissa Frizziero, Carmine Carbone, et al.
Critical Reviews in Oncology/Hematology|September 30, 2023
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statementLorenza Rimassa, Giovanni Brandi, Monica Niger, et al.
Expert Review of Molecular Diagnostics|March 17, 2018
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validationGeny Piro, Carmine Carbone, Raffaela Santoro, et al.
Frontiers in Pharmacology|May 4, 2013
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapyAnna Tamburrino, Geny Piro, Carmine Carbone, et al.
Current Opinion in Pharmacology|July 17, 2013
Rationale and clinical use of multitargeting anticancer agentsDavide Melisi, Geny Piro, Anna Tamburrino, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 18, 2017
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapyRaffaela Santoro, Carmine Carbone, Geny Piro, et al.
Anticancer Research|March 31, 2018
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional ActivityRaffaela Santoro, Marco Zanotto, Carmine Carbone, et al.
Expert Opinion on Drug Safety|April 2, 2014
Targeting the epidermal growth factor receptor in solid tumors: focus on safetyEleonora Lucchini, Sara Pilotto, Elisa Spada, et al.
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|December 27, 2005
Key cancer cell signal transduction pathways as therapeutic targetsRoberto Bianco, Davide Melisi, Fortunato Ciardiello, et al.
Current Pharmaceutical Design|October 25, 2014
Pancreatic cancer: systemic combination therapies for a heterogeneous diseaseDavide Melisi, Lorenzo Calvetti, Melissa Frizziero, et al.
Current Drug Metabolism|August 13, 2015
Current Strategies to Overcome Resistance to ALK-Inhibitor AgentsFrancesca Simionato, Melissa Frizziero, Carmine Carbone, et al.
Critical Reviews in Oncology/Hematology|September 30, 2023
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statementLorenza Rimassa, Giovanni Brandi, Monica Niger, et al.
Expert Review of Molecular Diagnostics|March 17, 2018
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validationGeny Piro, Carmine Carbone, Raffaela Santoro, et al.
Frontiers in Pharmacology|May 4, 2013
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapyAnna Tamburrino, Geny Piro, Carmine Carbone, et al.
Current Opinion in Pharmacology|July 17, 2013
Rationale and clinical use of multitargeting anticancer agentsDavide Melisi, Geny Piro, Anna Tamburrino, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 18, 2017
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapyRaffaela Santoro, Carmine Carbone, Geny Piro, et al.
Anticancer Research|March 31, 2018
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional ActivityRaffaela Santoro, Marco Zanotto, Carmine Carbone, et al.
Expert Opinion on Drug Safety|April 2, 2014
Targeting the epidermal growth factor receptor in solid tumors: focus on safetyEleonora Lucchini, Sara Pilotto, Elisa Spada, et al.
Pageof 13